Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

Do you consider a stock's growth and sales trends when comparing names? For ideas on how to start your own sales analysis, we ran a screen.

We began by screening the healthcare sector for stocks with high growth prospects, with 5-year projected EPS growth above 15%. This is important because of the current legislation around healthcare in the United States, the market seems to think the names in our universe have the qualities to excel in a changing climate.

We then screened these names for those with strong trends in revenue compared with inventory over the last year. We screened for companies seeing faster growth in revenue than inventory over the last year. Since inventory represents the portion of goods not yet sold, faster growth in revenue than inventory is considered a good sign.

To screen for healthy liquidity, we also only focused on those companies with inventory declining as a percent of current assets.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.

Do you think these companies have strong sales trends? Use this list as a starting point for your own analysis.

1. Natus Medical Inc. (BABY): Develops, manufactures, and markets neurodiagnostic and newborn care products worldwide. Market cap at $325.86M, most recent closing price at $10.88. Revenue grew by 57.23% during the most recent quarter ($80.72M vs. $51.34M y/y). Inventory grew by 1.22% during the same time period ($40.76M vs. $40.27M y/y). Inventory, as a percentage of current assets, decreased from 31.4% to 25.94% during the most recent quarter (comparing 3 months ending 2012-09-30 to 3 months ending 2011-09-30). 5-year EPS growth at 19%.

2. BioMarin Pharmaceutical Inc. (BMRN): Develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Market cap at $5.82B, most recent closing price at $46.96. Revenue grew by 12.96% during the most recent quarter ($128.12M vs. $113.42M y/y). Inventory grew by 4.5% during the same time period ($120.83M vs. $115.63M y/y). Inventory, as a percentage of current assets, decreased from 23.74% to 16.8% during the most recent quarter (comparing 3 months ending 2012-09-30 to 3 months ending 2011-09-30). 5-year EPS growth at 36%.

3. China Biologic Products, Inc. (CBPO): Engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. Market cap at $378.09M, most recent closing price at $14.23. Revenue grew by 28.62% during the most recent quarter ($53.12M vs. $41.3M y/y). Inventory grew by 3.68% during the same time period ($68.24M vs. $65.82M y/y). Inventory, as a percentage of current assets, decreased from 38.27% to 30.51% during the most recent quarter (comparing 3 months ending 2012-09-30 to 3 months ending 2011-09-30). 5-year EPS growth at 30%.

4. Neogen Corp. (NEOG): Develops, manufactures, and markets various products for food and animal safety worldwide. Market cap at $1.09B, most recent closing price at $45.73. Revenue grew by 8.82% during the most recent quarter ($49.73M vs. $45.7M y/y). Inventory grew by 2.31% during the same time period ($35.01M vs. $34.22M y/y). Inventory, as a percentage of current assets, decreased from 27.55% to 22.92% during the most recent quarter (comparing 3 months ending 2012-08-31 to 3 months ending 2011-08-31). 5-year EPS growth at 20%.

5. Novo Nordisk A/S (NVO): Engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. Market cap at $72.94B, most recent closing price at $161.20. Revenue grew by 20.04% during the most recent quarter ($19,845M vs. $16,532M y/y). Inventory grew by 3.96% during the same time period ($9,414M vs. $9,055M y/y). Inventory, as a percentage of current assets, decreased from 23.34% to 23.02% during the most recent quarter (comparing 3 months ending 2012-09-30 to 3 months ending 2011-09-30). 5-year EPS growth at 18%

6. Nxstage Medical, Inc. (NXTM): Engages in the development, manufacture, and marketing of products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures in the United States. Market cap at $653.54M, most recent closing price at $11.06. Revenue grew by 9.39% during the most recent quarter ($61.15M vs. $55.9M y/y). Inventory grew by -1.91% during the same time period ($34.88M vs. $35.56M y/y). Inventory, as a percentage of current assets, decreased from 22.59% to 21.93% during the most recent quarter (comparing 3 months ending 2012-09-30 to 3 months ending 2011-09-30). 5-year EPS growth at 20%

7. ResMed Inc. (RMD): Engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Market cap at $5.94B, most recent closing price at $41.53. Revenue grew by 7.93% during the most recent quarter ($339.73M vs. $314.77M y/y). Inventory grew by 2.78% during the same time period ($193.17M vs. $187.95M y/y). Inventory, as a percentage of current assets, decreased from 16.45% to 13.32% during the most recent quarter (comparing 3 months ending 2012-09-30 to 3 months ending 2011-09-30). 5-yea EPS growth at 18%.

Accounting data sourced from Google Finance, all other data sourced from Finviz.

Source: 7 High Growth Healthcare Stocks With Strong Inventory Trends